BR112018077257A2 - derivados de 5,7-di-hidro-pirrolo-piridina para o tratamento de doenças neurológicas e neurodegenerativas - Google Patents
derivados de 5,7-di-hidro-pirrolo-piridina para o tratamento de doenças neurológicas e neurodegenerativasInfo
- Publication number
- BR112018077257A2 BR112018077257A2 BR112018077257-7A BR112018077257A BR112018077257A2 BR 112018077257 A2 BR112018077257 A2 BR 112018077257A2 BR 112018077257 A BR112018077257 A BR 112018077257A BR 112018077257 A2 BR112018077257 A2 BR 112018077257A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- neurological
- pyrrole
- dihydro
- neurodegenerative diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
a presente invenção refere-se, em parte, a compostos de fórmula (i), ou um n-óxido dos mesmos, ou um sal farmaceuticamente aceitável do composto ou do n-óxido, em que: r1, r2, l, a, e e são como aqui descrito, processos para a preparação de; intermediários usados na preparação de; e composições contendo tais compostos, n-óxidos, ou sais, e seus usos para o tratamento de distúrbios mediados por m4 (ou associados a m4) incluindo, por exemplo, doença de alzheimer, esquizofrenia (por exemplo, seus sintomas cognitivos e negativos), dor, vício, e um distúrbio do sono.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662357624P | 2016-07-01 | 2016-07-01 | |
US62/357,624 | 2016-07-01 | ||
US201662372421P | 2016-08-09 | 2016-08-09 | |
US62/372,421 | 2016-08-09 | ||
PCT/IB2017/053565 WO2018002760A1 (en) | 2016-07-01 | 2017-06-15 | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018077257A2 true BR112018077257A2 (pt) | 2019-04-02 |
Family
ID=59215839
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018077257-7A BR112018077257A2 (pt) | 2016-07-01 | 2017-06-15 | derivados de 5,7-di-hidro-pirrolo-piridina para o tratamento de doenças neurológicas e neurodegenerativas |
Country Status (21)
Country | Link |
---|---|
US (4) | US10604519B2 (pt) |
EP (2) | EP3872078A1 (pt) |
JP (1) | JP7046018B2 (pt) |
KR (1) | KR102470497B1 (pt) |
CN (1) | CN109641898B (pt) |
AU (1) | AU2017286868B2 (pt) |
BR (1) | BR112018077257A2 (pt) |
CA (1) | CA2972070A1 (pt) |
DK (1) | DK3478679T3 (pt) |
ES (1) | ES2878160T3 (pt) |
HU (1) | HUE054857T2 (pt) |
IL (1) | IL263912B (pt) |
MX (1) | MX2019000231A (pt) |
PH (1) | PH12019500004A1 (pt) |
PL (1) | PL3478679T3 (pt) |
PT (1) | PT3478679T (pt) |
SG (1) | SG11201811712QA (pt) |
TW (1) | TWI736642B (pt) |
UY (1) | UY37311A (pt) |
WO (1) | WO2018002760A1 (pt) |
ZA (1) | ZA201900519B (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3634408B1 (en) | 2017-06-09 | 2022-12-28 | Merck Sharp & Dohme LLC | Azabicyclo[4.1.0]heptane allosteric modulators of the m4 muscarinic acetylcholine receptor |
EP3642202B1 (en) * | 2017-06-22 | 2022-11-02 | Pfizer Inc. | Dihydro-pyrrolo-pyridine derivatives |
JP2023502445A (ja) | 2019-11-22 | 2023-01-24 | エフ.ホフマン-ラ ロシュ アーゲー | ピロリジン誘導体 |
CN112174869B (zh) * | 2020-10-12 | 2023-04-25 | 蔡霈 | N-苯乙酰基-2-羟甲基吡咯烷-2-甲酰胺的制备方法及其药用用途 |
WO2022235514A1 (en) * | 2021-05-04 | 2022-11-10 | Mind Medicine, Inc. | Liposome delivery of psychedelics |
WO2024061253A1 (zh) * | 2022-09-23 | 2024-03-28 | 苏州科睿思制药有限公司 | Emraclidine的晶型及其制备方法和用途 |
WO2024088409A1 (zh) * | 2022-10-28 | 2024-05-02 | 纽欧申医药(上海)有限公司 | 一种含氮杂环化合物、其药学上可接受的盐及其制备方法与应用 |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1308461A3 (en) | 1993-01-25 | 2004-02-11 | Takeda Chemical Industries, Ltd. | Antibodies to beta-amyloids or their derivatives and use thereof |
DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
EP0994728B1 (en) | 1997-04-09 | 2008-07-30 | Intellect Neurosciences, Inc. | Recombinant antibodies specific for beta-amyloid ends, dna encoding and methods of use thereof |
GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
PL218883B1 (pl) | 2000-02-24 | 2015-02-27 | Lilly Co Eli | Kompozycja farmaceutyczna zawierająca przeciwciało do zastosowania w leczeniu klinicznej lub przedklinicznej choroby Alzheimera |
DE10045112A1 (de) | 2000-09-11 | 2002-03-21 | Merck Patent Gmbh | Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems |
CA2427661C (en) | 2000-11-03 | 2013-05-28 | Proteotech, Inc. | Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants |
WO2003016466A2 (en) | 2001-08-17 | 2003-02-27 | Eli Lilly And Company | ANTI-Aβ ANTIBODIES |
US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
BR0315157A (pt) | 2002-10-09 | 2005-08-09 | Rinat Neuroscience Corp | Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste |
US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
JP2006527756A (ja) | 2003-06-19 | 2006-12-07 | ファイザー・プロダクツ・インク | Nk1拮抗薬 |
US20070031416A1 (en) | 2003-09-09 | 2007-02-08 | Takeda Pharmaceutical Company Limited | Use of antibody |
GB0327319D0 (en) | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
CA2555071A1 (en) | 2004-02-02 | 2005-09-01 | Pfizer Products Inc. | Histamine-3 receptor modulators |
US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
EP1595881A1 (en) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
EP2298807A3 (en) | 2004-07-30 | 2011-05-18 | Rinat Neuroscience Corp. | Antibodies directed against amyloid-beta peptide and methods using same |
GB0423356D0 (en) | 2004-10-21 | 2004-11-24 | Merck Sharp & Dohme | Therapeutic agents |
DK1807434T3 (da) | 2004-10-25 | 2010-11-22 | Lilly Co Eli | Thienopyridiner som allosteriske potentiatorer af M4- muscarinreceptoren |
US20090074775A1 (en) | 2004-12-22 | 2009-03-19 | David Michael Holtzman | Use Of Anti-AB Antibody To Treat Traumatic Brain Injury |
UY29504A1 (es) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
US8227475B2 (en) | 2005-05-12 | 2012-07-24 | Pfizer Inc. | Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide |
WO2006126083A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors |
WO2006126081A2 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors |
CA2608672A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3,4-b] pyrazinones as pde-5 inhibitors |
US7812040B2 (en) | 2005-06-22 | 2010-10-12 | Pfizer Inc. | Histamine-3 receptor antagonists |
TW200713011A (en) | 2005-09-30 | 2007-04-01 | Hon Hai Prec Ind Co Ltd | System, method and electrical apparatus for data transferring |
US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
JP2009514846A (ja) | 2005-11-04 | 2009-04-09 | ファイザー・リミテッド | テトラヒドロナフチリジン誘導体 |
WO2007063385A2 (en) | 2005-12-01 | 2007-06-07 | Pfizer Products Inc. | Spirocyclic amine histamine-3 receptor antagonists |
WO2007069053A1 (en) | 2005-12-14 | 2007-06-21 | Pfizer Products Inc. | Benzimidazole antagonists of the h-3 receptor |
WO2007088462A1 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Spirochromane antagonists of the h-3 receptor |
WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
WO2007099423A1 (en) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
JP2009539762A (ja) | 2006-03-13 | 2009-11-19 | ファイザー・プロダクツ・インク | H3受容体のテトラリン拮抗薬 |
DK2013208T3 (da) | 2006-04-21 | 2011-08-15 | Pfizer Prod Inc | Pyridin[3,4-B]pyrazinoner |
WO2007138431A2 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
CN1869036A (zh) * | 2006-06-30 | 2006-11-29 | 中国药科大学 | 7-取代-3-氯吡咯并[3,4-b]吡啶化合物 |
DK2124933T3 (da) | 2007-01-22 | 2012-11-19 | Pfizer Prod Inc | Tosylatsalt af en terapeutisk forbindelse og farmaceutiske sammensætninger deraf |
US8664234B2 (en) | 2010-10-04 | 2014-03-04 | Merck Sharp & Dohme Corp. | Dihydrobenzoquinazolinone M1 receptor positive allosteric modulators |
MX2013005454A (es) * | 2010-11-15 | 2013-06-24 | Abbvie Inc | Inhibidores de nampt y rock. |
CA2831334A1 (en) * | 2011-04-08 | 2012-10-11 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
EP2712655B1 (en) * | 2011-04-28 | 2019-12-18 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
JP6101279B2 (ja) * | 2011-11-15 | 2017-03-22 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Gpr119アゴニストとして有用な置換シクロプロピル化合物 |
US8741892B2 (en) * | 2011-12-05 | 2014-06-03 | Boehringer Ingelheim International Gmbh | Compounds |
US8642774B2 (en) * | 2011-12-08 | 2014-02-04 | Boehringer Ingelheim International Gmbh | Compounds |
US9493481B2 (en) | 2012-02-23 | 2016-11-15 | Vanderbilt University | Substituted 5-aminothieno[2,3—C]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M4 |
WO2014035829A1 (en) * | 2012-08-31 | 2014-03-06 | Vanderbilt University | Substituted 3-aminothieno[2,3-c]pyridine-2-carboxamide analogs as positive allosteric modulators |
WO2015027204A1 (en) | 2013-08-23 | 2015-02-26 | Vanderbilt University | Substituted thieno[2,3-b]pyridine-2-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
WO2015027214A1 (en) | 2013-08-23 | 2015-02-26 | Vanderbilt University | Substituted thieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4 |
US11497586B2 (en) | 2014-03-21 | 2022-11-15 | Align Technology, Inc. | Segmented orthodontic appliance with elastics |
DK3102568T3 (en) | 2014-02-06 | 2018-10-08 | Heptares Therapeutics Ltd | BICYCLIC AZA RELATIONS AS MUSCARIN-M1 RECEPTOR AGONISTS |
-
2017
- 2017-06-15 EP EP21167379.3A patent/EP3872078A1/en active Pending
- 2017-06-15 PL PL17733044T patent/PL3478679T3/pl unknown
- 2017-06-15 MX MX2019000231A patent/MX2019000231A/es unknown
- 2017-06-15 KR KR1020197002851A patent/KR102470497B1/ko active IP Right Grant
- 2017-06-15 BR BR112018077257-7A patent/BR112018077257A2/pt active Search and Examination
- 2017-06-15 ES ES17733044T patent/ES2878160T3/es active Active
- 2017-06-15 SG SG11201811712QA patent/SG11201811712QA/en unknown
- 2017-06-15 CN CN201780053245.2A patent/CN109641898B/zh active Active
- 2017-06-15 WO PCT/IB2017/053565 patent/WO2018002760A1/en unknown
- 2017-06-15 DK DK17733044.6T patent/DK3478679T3/da active
- 2017-06-15 PT PT177330446T patent/PT3478679T/pt unknown
- 2017-06-15 JP JP2018568716A patent/JP7046018B2/ja active Active
- 2017-06-15 HU HUE17733044A patent/HUE054857T2/hu unknown
- 2017-06-15 EP EP17733044.6A patent/EP3478679B1/en active Active
- 2017-06-15 AU AU2017286868A patent/AU2017286868B2/en active Active
- 2017-06-28 CA CA2972070A patent/CA2972070A1/en active Pending
- 2017-06-28 TW TW106121650A patent/TWI736642B/zh active
- 2017-06-29 US US15/637,071 patent/US10604519B2/en active Active
- 2017-06-30 UY UY0001037311A patent/UY37311A/es not_active Application Discontinuation
-
2018
- 2018-12-23 IL IL263912A patent/IL263912B/en unknown
-
2019
- 2019-01-03 PH PH12019500004A patent/PH12019500004A1/en unknown
- 2019-01-24 ZA ZA2019/00519A patent/ZA201900519B/en unknown
-
2020
- 2020-02-21 US US16/797,966 patent/US20200207762A1/en not_active Abandoned
-
2021
- 2021-06-01 US US17/335,666 patent/US11905284B2/en active Active
-
2023
- 2023-02-21 US US18/112,156 patent/US20230192690A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
DK3478679T3 (da) | 2021-06-21 |
KR20190035713A (ko) | 2019-04-03 |
ES2878160T3 (es) | 2021-11-18 |
CA2972070A1 (en) | 2018-01-01 |
WO2018002760A1 (en) | 2018-01-04 |
EP3478679A1 (en) | 2019-05-08 |
TW201811780A (zh) | 2018-04-01 |
ZA201900519B (en) | 2022-07-27 |
MX2019000231A (es) | 2019-08-29 |
TWI736642B (zh) | 2021-08-21 |
PH12019500004A1 (en) | 2019-10-21 |
US10604519B2 (en) | 2020-03-31 |
US20200207762A1 (en) | 2020-07-02 |
IL263912B (en) | 2022-04-01 |
US20180002331A1 (en) | 2018-01-04 |
EP3872078A1 (en) | 2021-09-01 |
PT3478679T (pt) | 2021-06-30 |
AU2017286868B2 (en) | 2021-11-11 |
EP3478679B1 (en) | 2021-04-21 |
UY37311A (es) | 2018-01-31 |
HUE054857T2 (hu) | 2021-10-28 |
JP7046018B2 (ja) | 2022-04-01 |
CN109641898B (zh) | 2022-04-08 |
US20210309659A1 (en) | 2021-10-07 |
PL3478679T3 (pl) | 2021-10-25 |
CN109641898A (zh) | 2019-04-16 |
AU2017286868A1 (en) | 2019-02-21 |
US11905284B2 (en) | 2024-02-20 |
JP2019519583A (ja) | 2019-07-11 |
SG11201811712QA (en) | 2019-01-30 |
US20230192690A1 (en) | 2023-06-22 |
IL263912A (en) | 2019-01-31 |
KR102470497B1 (ko) | 2022-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018077257A2 (pt) | derivados de 5,7-di-hidro-pirrolo-piridina para o tratamento de doenças neurológicas e neurodegenerativas | |
BR112018000041A2 (pt) | Derivados de carbamato de 1,1,1-trifluoro-3- hidroxipropan-2-ila e derivados de carbamato de 1,1,1-trifluoro-4-hidroxibutan-2-ila como inibidores de magl | |
TW201613890A (en) | Pyridine derivatives as muscarinic M1 receptor positive allosteric modulators | |
BR112015021336A2 (pt) | compostos 1,3-oxazin-2-amina fundidos ciclopropil perfluorados como inibidores de beta-secretase e métodos de uso | |
EA201692132A1 (ru) | Изоиндолин-1-оновые производные в качестве положительных аллостерических модуляторов холинергического мускаринового m1 рецептора для лечения болезни альцгеймера | |
BR112014003496A2 (pt) | derivado heterocíclico e fármaco | |
BR112015021701A2 (pt) | novos compostos inibidores da fosfoestearase tipo 10a | |
BR112015027055A2 (pt) | compostos de bi-heteroarila e usos dos mesmos | |
BR112015010412A2 (pt) | compostos heteroaromáticos e seu uso como ligantes de dopamina d1 | |
EA201890650A1 (ru) | ПРОИЗВОДНЫЕ 8-[6-[3-(АМИНО)ПРОПОКСИ]-3-ПИРИДИЛ]-1-ИЗОПРОПИЛ-ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА В КАЧЕСТВЕ СЕЛЕКТИВНЫХ МОДУЛЯТОРОВ КИНАЗЫ МУТАЦИИ АТАКСИИ-ТЕЛЕАНГИЭКТАЗИИ (ATM) ДЛЯ ЛЕЧЕНИЯ РАКА | |
BR112015029512A8 (pt) | derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas | |
BR112013020605A2 (pt) | derivados de 6-ciclobutil-1,5-diidro-pirazol[3,4-d]pirimidin-4-ona e seu uso como inibidores de pde9a | |
BR112018013955A2 (pt) | ligantes de dopamina d3 de 6,7,8,9-tetra-hidro-5h-pirido[2,3-d]azepina | |
EA201200952A1 (ru) | Производные пиразина и их применение для лечения неврологических нарушений | |
BR112013020536A2 (pt) | 1,4-oxazepinas como inibidores de bace1 e/ou bace2 | |
BR112014003079A2 (pt) | derivado de 1,2,3,4-tetra-hidroquinolina útil para o tratamento de diabetes | |
BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
BR112014001908A2 (pt) | derivados aza heterocíclicos substituídos | |
BR112018069111A2 (pt) | terapia de combinação para o tratamento de leucemia mieloide aguda | |
BR112014024479A8 (pt) | Formulações farmacêuticas compreendendo antagonistas de c-cr3 | |
BR112014028813A2 (pt) | 5-amino[1,4]tiazinas como inibidores bace1 | |
BR112015030678A8 (pt) | derivados 4-amino-6-fenil-5,6-di-hidroimidazo [1,5-a] pirazina como inibidores de beta-secretase (bace), composição farmacêutica, processo para preparação da mesma, e usos na fabricação de medicamentos | |
MX2017003470A (es) | Inhibidores macrociclicos de cinasa lrrk2. | |
BR112022005595A2 (pt) | Composto, medicamento, métodos para inibir histona deacetilase 6 e para profilaxia ou tratamento de doença de alzheimer ou paralisia supranuclear progressiva em um mamífero, e, uso de composto | |
BR112020022088A8 (pt) | Moduladores alostéricos de espiropiperidina de receptores nicotínicos de acetilcolina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |